Navigation Links
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Date:5/28/2008

rcialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Announces Upcoming Conference Participation
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
6. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... 30, 2014 Nematicide is a type ... are microscopic parasitic roundworms, found in massive quantities ... plants and animals. Nematicides have tended to be ... promoting migration through the soil. A single gram ... nematodes. With more than 10,000 species classified, they ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... May 4, 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE ... graft material, today announced that its chairman and CEO, Guy ... Annual Equity Conference at the Hard Rock Hotel in Hollywood, ... At the time of the presentation, a live ...
... Neb., May 4, 2011 Transgenomic, Inc. (OTC/BB: ... Brugada Syndrome (BrS) test panel at the 2011 Heart Rhythm ... of 9 genes and broadens the test indication to include ... "The addition of two newly identified J-wave syndrome genes, ...
... May 4, 2011 NxStage Medical, Inc. (Nasdaq: ... products, today reported financial results for the first quarter ... above the top end of its guidance range. ... quarter of 2011 increased 25 percent to a record ...
Cached Biology Technology:Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings 2Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings 3Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings 4NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 2NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 3NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 4NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 5NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 6NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 7
(Date:9/30/2014)... . , Animals ... such as exposure to predators. Researchers from the Max ... study on different populations of great tits that risk-taking ... High metabolic rates and low temperatures were associated with ... more likely to approach potential predators. , The readiness ...
(Date:9/30/2014)... who suffer from asthma may think there,s not a ... properly taking medications and avoiding allergic triggers. , ... of Allergy, Asthma and Immunology , the scientific publication ... (ACAAI), asthma sufferers can learn lessons about managing their ... the Annals article improved her asthma once she and ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... sinister about epilepsy: the disease affects the very core ... lead to seizures throughout the body or in parts of ... possible. The causes are still only partially understood but ... or metabolic diseases have been implicated. Epilepsy is not ...
... February 1, 2013 Poor impulse control contributes ... rewarding substances, like food, alcohol, and other drugs. ... FDA-approved medications for alcoholism, like naltrexone (Revia) and ... by curbing cravings and creating unpleasant reactions to ...
... levels of greenhouse gases, particularly carbon dioxide (CO2), ... fuels, deforestation, cultivation of grasslands, drainage of the ... shifts in climate patterns have led scientists to ... and to develop methods to evaluate how changes ...
Cached Biology News:Cats and humans suffer from similar forms of epilepsy 2If you are impulsive, take modafinil and count to 10 2New protocol recommendations for measuring soil organic carbon sequestration 2New protocol recommendations for measuring soil organic carbon sequestration 3New protocol recommendations for measuring soil organic carbon sequestration 4
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
... AmpliTaq Gold® DNA Polymerase is a ... When the chemical moiety is attached to ... set-up and the first ramp of thermal ... non-optimal annealing temperatures), the enzyme is inactive. ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: